To further examine the role of BRAF mutational status on kinase activity, and as a mean to validate results obtained with patient specimens, we profiled the kinase activity of lysates from the three melanoma cell lines MelJD (BRAF wild-type), patient-3-post (BRAF(V600E)/“vemurafenib-resistant”) and MM200 (BRAF(V600E)/“vemurafenib-sensitive”). The gene discussed is BRAF; the disease is melanoma.